Publications by authors named "Timothy A Dixon"
Influenza outbreaks are a major burden worldwide annually. While seasonal vaccines do provide protection against infection, they are limited in that they need to be updated every year to account for the constantly mutating virus. Recently, lipid nanoparticles (LNPs) encapsulating mRNA have seen major success as a vaccine platform for SARS-CoV-2.
View Article and Find Full Text PDFVaccines represent a pivotal health advancement for preventing infection. However, because carrier systems with repeated administration can invoke carrier-targeted immune responses that diminish subsequent immune responses (e.g.
View Article and Find Full Text PDFArticle Synopsis
- Influenza virus outbreaks pose a significant global health challenge each year, with current vaccines often ineffective due to changes in the virus and low immune responses.
- COBRA hemagglutinin (HA) immunogens show promise in addressing viral mutations but require adjuvants to enhance their effectiveness, with STING agonists demonstrating potential in this role.
- This study explores a new vaccine platform using acetalated dextran microparticles with COBRA HA and a STING agonist in mouse models, revealing varying efficacy across different genetic backgrounds and health conditions, emphasizing the need for targeted adjuvant strategies.